 SAN DIEGO, Aug. 5, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2021 and recent corporate updates. We continue to aggressively advance our clinical and growing preclinical pipeline of oncology programs, said Charles M. 